PepGen Inc. (PEPG): Cash & Equivalents
$60.51M
As of 2025-12-31
$22.76M
As of 2026-06-30
-30.7%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $60.51M | +22.4% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $49.42M | -38.8% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $80.77M | -55.6% | 2025-02-24, Balance as of period end |
| 2022-12-31 | $181.75M | +36.8% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $132.90M | n/a | 2023-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| PepGen Inc. (PEPG) | 2025-12-31 | $60.51M | +22.4% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $37.73M | -18.1% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $22.81M | +11.0% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $28.49M | +65.7% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $35.69M | -59.1% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $37.07M | +213.8% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $179.97M | +84.1% |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $1.64M | n/m |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $176.48M | +4.9% |
Compare PEPG, GOSS, ELDN, CRBP side by side · Screen every company in Pharmaceutical Preparations ↗